title: Psychological Symptoms Among Patients With BCR-ABL-Negative Myeloproliferative Neoplasms.
abstract: BCR-ABL-negative myeloproliferative neoplasms (MPNs) represent a heterogeneous group of diseases, including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). Psychological manifestations among these diseases have not been adequately described.
  
  
  
  Cross-sectional surveys measuring distress, anxiety, and depression were collected from patients with BCR-ABL-negative MPNs from May 2015 to October 2015. Participants provided demographic information and completed the Distress Thermometer and Problem List (DT&PL) to assess distress and the Hospital Anxiety and Depression Scale (HADS) to assess distress, anxiety, and depression. They provided information on how their MPN affected their lives.
  
  
  
  Of the 117 participants, 31.2% had PV, 28.4% had ET, 28.4% had MF, and 11.9% had another type of MPN. Time with MPN varied from less than 1 year (7.5%), 1 to 3 years (19.8%), 3 to 5 years (23.6%), 5 to 10 years (19.8%), and more than 10 years (29.2%). Distress averaged 3.14 (SD, 2.83; DT&PL), with 40.4% meeting NCCN criteria for distress, and averaged 8.97 (SD, 7.44; HADS), with 38.5% meeting HADS criteria for distress. Anxiety averaged 5.54 (SD, 4.37), with 31.3% meeting HADS criteria for anxiety. Depression averaged 3.4 (SD, 3.4), with 12.5% meeting HADS criteria for depression. Distress was higher for PV (3.86), MF (3.12), and "other" MPN (4.33) than it was for ET (1.81; P=.016). Distress was more common in non-white patients (P=.015) and those with either PV or MF but not ET (DT&PL ≥4; P=.038). Patients' comments described coping strategies or symptom burden.
  
  
  
  Distress and anxiety are highly prevalent with BCR-ABL-negative MPNs and may correspond to disease-related symptom burden. These findings deserve further study.
authors.affiliation: From Division of Network Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, West Harrison; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, New York; and Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Daniel C
authors.initials: DC
authors.lastname: McFarland
authors.affiliation: From Division of Network Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, West Harrison; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, New York; and Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Heather
authors.initials: H
authors.lastname: Polizzi
authors.affiliation: From Division of Network Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, West Harrison; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, New York; and Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: John
authors.initials: J
authors.lastname: Mascarenhas
authors.affiliation: From Division of Network Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, West Harrison; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, New York; and Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Marina
authors.initials: M
authors.lastname: Kremyanskaya
authors.affiliation: From Division of Network Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, West Harrison; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, New York; and Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Jimmie
authors.initials: J
authors.lastname: Holland
authors.affiliation: From Division of Network Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, West Harrison; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, New York; and Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Ronald
authors.initials: R
authors.lastname: Hoffman
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy / Q000453:epidemiology*; D003430:Cross-Sectional Studies; D003863:Depression / Q000188:drug therapy / Q000453:epidemiology*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011087:Polycythemia Vera / Q000378:metabolism / Q000523:psychology*; D015995:Prevalence; D055728:Primary Myelofibrosis / Q000378:metabolism / Q000523:psychology*; D012737:Sex Factors; D013315:Stress, Psychological / Q000188:drug therapy / Q000453:epidemiology*; D013920:Thrombocythemia, Essential / Q000378:metabolism / Q000523:psychology*; D013997:Time Factors
chemical_list: D000928:Antidepressive Agents; D016044:Fusion Proteins, bcr-abl